US Market News
4日前
Atlas Healthcare Physicians to Cover Cardio Diagnostics’ Precision Cardiovascular Medicine Tests Across Its NetworkJune 24, 2026 8:35 AM
Business Wire Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians (AHP), a community-driven, independent physician association (IPA) based in Southern California, will cover Cardio Diagnostics’ tests, Epi+Gen CHD™ and PrecisionCHD™, for their members with prior authorization beginning May 2026. AHP consists of an expansive network of primary care and specialists, hospitals, and ancillary providers serving managed care populations across Los Angeles and Orange County. Providers will recommend Epi+Gen CHD™ or PrecisionCHD™ based on a patient’s medical history. Epi+Gen CHD™ assesses the three-year risk of a coronary heart disease (CHD) event, including a heart attack. PrecisionCHD™ aids in diagnosing CHD and provides the specific molecular drivers of CHD for each patient to help inform more personalized care. Epi+Gen CHD™ and PrecisionCHD™ are simple, physician-ordered blood tests that do not require exposure to radiation or fasting. As a result, they seamlessly integrate into clinical workflows and do not require specialized infrastructure to administer. “At Atlas Healthcare Physicians, we are committed to providing our physicians with innovative tools that support earlier detection, personalized treatment planning, and improved patient outcome,” said Tam Doan, MBA, Chief Operating Officer of Atlas Healthcare Physicians. “Our collaboration with Cardio Diagnostics reflects our shared commitment to expanding access to advanced cardiovascular diagnostics, empowering providers to make more informed clinical decisions, and helping patients better manager their heart health.” “IPAs are uniquely positioned to drive better cardiovascular outcomes across their member populations and the right precision medicine tools can make a meaningful difference,” remarked Meesha Dogan, PhD, CEO and Co-Founder of Cardio Diagnostics. “By covering Epi+Gen CHD™ and PrecisionCHD™, AHP is giving its providers the ability to identify risk earlier, tailor care to each patient’s unique cardiovascular profile, and avoid costly downstream interventions that come from delayed or missed diagnoses. That’s a win for patients, for providers, and for the network.” According to the California Department of Public Health, cardiovascular disease is a leading cause of death in California — and the largest economic burden on the state. While cardiovascular care places a significant cost challenge at both a state and national level, the cost of delaying action until symptoms manifest is far greater. This partnership reflects Cardio Diagnostics’ continued expansion of access to precision cardiovascular medicine across the United States. About Atlas Healthcare Physicians AHP is an IPA dedicated to improving the health and well-being of communities throughout Southern California. AHP partners with primary care and specialists, hospitals, and ancillary providers to deliver coordinated, high-quality healthcare to managed care populations across Los Angeles and Orange County. Through a commitment to provider support, operational excellence, and innovative healthcare solutions, AHP empowers its network to deliver accessible, patient-centered care while advancing quality outcomes and value-based healthcare initiatives. About Cardio Diagnostics Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/ Forward-Looking Statements Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2025, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20260624992562/en/ Investors
Investor Relations
855-226-9991
investors@cdio.ai Media & Public Relations
Public Relations
855-226-9991
pr@cdio.ai Original: Atlas Healthcare Physicians to Cover Cardio Diagnostics’ Precision Cardiovascular Medicine Tests Across Its Network
US Market News
1月前
Cardio Diagnostics Holdings, Inc. to Showcase Precision Cardiovascular Solutions at Four National Benefits Conferences in JuneMay 27, 2026 8:35 AM
Business Wire These evidence-based solutions help employers, brokers, and unions tackle cardiovascular disease, a leading driver of medical claims and lost productivity. Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced that the company will exhibit at four upcoming national benefits conferences, connecting with employers, brokers, union trustees, and plan administrators on a shared challenge: cardiovascular disease (CVD). CVD remains a leading medical claims cost driver for most health plans and a major contributor to absenteeism, disability, and lost workforce productivity. Cardio Diagnostics’ clinically validated blood tests, Epi+Gen CHD™ and PrecisionCHD™, combine epigenetics, genetics, and AI to help identify at-risk individuals before a life-threatening, costly cardiac event occurs. These tests go beyond proxy biomarkers for heart disease, such as cholesterol and blood pressure, to help improve plan member outcomes while equipping benefit leaders and organizations with an effective cost reduction strategy and helping brokers improve client retention. Paired with HeartRisk™, the company’s HIPAA-compliant real-time population insights platform, plan sponsors can benchmark cardiovascular risk across their workforce or membership, project both direct and indirect costs, and target benefits where they may have the greatest impact. Cardio Diagnostics will be exhibiting at the following conferences in June: Greater Philadelphia Business Coalition on Health (GPBCH) Annual Conference — June 4, 2026, Philadelphia, PA. Conner Strong & Buckelew (CSB) Health & Benefits Innovation Summit — June 9, 2026, Philadelphia, PA. Midwest Employee Benefit Funds (MEBFC) Coalition, Inc. Annual Meeting — June 12, 2026, Countryside, IL. Onsite Employee Health & Wellness Centers Conference — June 25-26, 2026, Chicago, IL. Closing the Gap on a Preventable Crisis According to the World Heart Federation, an estimated 80% of CVD can be prevented. Yet, CVD is one of the leading combined direct and indirect cost drivers of benefits plans. These rising costs can impact broker satisfaction while straining the budgets of employers and union funds. Cardio Diagnostics’ solutions can help to address this challenge. Epi+Gen CHD™ can identify individuals at higher risk for a heart attack or sudden cardiac death in the next three years, even when traditional risk factors like cholesterol and blood pressure appear normal. PrecisionCHD™ helps detect molecular signals associated with coronary heart disease before major symptoms or events may occur. When implemented, they work together to help individuals take preventive action while helping employers, unions, and brokers reduce spend and support a healthier, more productive workforce. Meesha Dogan, PhD, CEO and Co-Founder of Cardio Diagnostics, highlighted the company’s unique position to partner with employers, brokers, and unions to tackle CVD. “The best benefits strategies do two things at once: bring spend down and keep individuals healthier. Cardiovascular disease presents an opportunity to do both. It’s a top claims driver, and it’s largely preventable when risk is identified early. Our precision tests and HeartRisk™ platform give plan sponsors a clear, individualized path to lower direct and indirect costs while keeping the workforce healthier, longer.” Connect with Cardio Diagnostics to Learn: How epigenetic and genetic biomarkers can identify cardiovascular risk that traditional testing methods may miss. Why earlier detection of heart disease can translate into measurable claims reductions and fewer lost workdays. How our blood tests can be seamlessly integrated into an onsite clinic’s workflow to help deliver more personalized care for plan members. Practical models for integrating precision cardiovascular testing into existing wellness, chronic care, and benefits programs. To learn more about Cardio Diagnostics, meet with our team at any of the upcoming conferences. About Cardio Diagnostics Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/. Forward-Looking Statements Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2025, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20260527302873/en/ Investors
Investor Relations
855-226-9991
investors @golfnut699-9991
pr@cdio.ai Original: Cardio Diagnostics Holdings, Inc. to Showcase Precision Cardiovascular Solutions at Four National Benefits Conferences in June
US Market News
4月前
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026February 18, 2026 11:17 AM
Business Wire
Please replace the release dated February 17, 2026 with the following corrected version due to multiple revisions.
The updated release reads:
CARDIO DIAGNOSTICS HOLDINGS, INC. TO HOST INVESTOR CALL ON THURSDAY, FEBRUARY 19, 2026
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, February 19, 2026, at 3 p.m. Central Time.
The call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives.
Webcast and Conference Call Details
Date: Thursday, February 19, 2026
Time: 3 p.m. Central Time
Webcast: https://www.cstproxy.com/cardiodiagnosticsinc/investorday/2026
To access the conference call by telephone, U.S. and Canada-based callers should dial 1 800-450-7155 (toll-free), and callers from outside the U.S. and Canada should dial +1 857-999-9155 (standard rates apply). Participants should use the passcode provided below to join.
Passcode: 3253181#
A replay of the webcast will be available via the webcast link above following the conclusion of the call.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ("Core Technology") for cardiovascular disease. For more information, please visit https://cdio.ai/.
Forward-Looking Statements
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will," "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, and dependence on results as discussed in the Annual Report on Form 10-K for the period ended December 31, 2024, under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260217161842/en/
Investors
Investor Relations
855-226-9991
investors@cdio.ai
Original: CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026
US Market News
4月前
Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026February 17, 2026 8:35 AM
Business Wire
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time.
The call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives.
Webcast and Conference Call Details
Date: Wednesday, February 18, 2026
Time: 3 p.m. Central Time
Webcast: https://www.cstproxy.com/cardiodiagnosticsinc/investorday/2026
To access the conference call by telephone, U.S. and Canada-based callers should dial 1 800-450-7155 (toll-free), and callers from outside the U.S. and Canada should dial +1 857-999-9155 (standard rates apply). Participants should use the passcode provided below to join.
Passcode: 3253181#
A replay of the webcast will be available via the webcast link above following the conclusion of the call.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ("Core Technology") for cardiovascular disease. For more information, please visit https://cdio.ai/.
Forward-Looking Statements
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will," "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, and dependence on results as discussed in the Annual Report on Form 10-K for the period ended December 31, 2024, under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260217161842/en/
Investors
Investor Relations
855-226-9991
investors@cdio.ai
Original: Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
ErnieBilco
4月前
glenn1919
4月前
tw0122
7月前
Monksdream
1年前
georgie18
1年前
Renee
1年前
getitrit
1年前
conix
2年前
メールアドレスで登録
